Breaking news and real-time updates from the ASX small-cap market
Artrya signs a five-year, US$0.5m minimum deal with HonorHealth, expanding its Salix cardiac imaging software across nine Arizona hospitals.
Clarity Pharmaceuticals wins FDA breakthrough status for prostate cancer PET agent 64Cu-SAR-bisPSMA, a major milestone for its copper theranostic program.
G8 Education enters exclusive talks over Majority Capital’s 26c-a-share takeover bid, a 160% premium, though no deal is guaranteed.
Austral Resources’ 4.75MW SAG mill has arrived at Rocklands, removing a major refurbishment risk as the copper project advances towards restart.
Inghams trims FY27 earnings guidance by up to $10m as weaker chicken prices and rising costs offset 5.3% volume growth.
Carnarvon Energy adds Pavo South-1 and Ara-1 to its Bedout drilling campaign, targeting prospects with a combined 265 million boe potential.
Nanoveu says its ECS-DoT-22 AI chip used up to 56 times less energy per inference than selected rivals and ran up to nine times faster.
Ardea Resources models US$509.8m NPV and a 59.6% IRR from scandium recovery at its Goongarrie nickel-cobalt hub, pending testing.
Talga’s Talnode-C anode has exceeded 8,000 cycles in a Japanese battery test, delivering up to five times the lifespan of conventional lithium-ion cells.
Cobalt Blue is prioritising its Kwinana cobalt refinery ahead of Broken Hill, putting downstream processing at the centre of its critical minerals strategy.
Future Metals is assessing a lower-capital pathway for its Panton project, including potential use of nearby Savannah processing infrastructure.
Aland Equity Group launches Elm Grove, its first capital-light property fund, targeting $3.37m in fees to June 2027 and $725,000 in investment returns.
